Body Vision Medical, a global leader in AI-powered intraoperative imaging, is proud to announce that its LungVision advanced imaging system has received regulatory approval from ANVISA, Brazil’s National Health Surveillance Agency. This approval marks another significant step forward in the company’s mission to improve early and accurate lung cancer diagnosis around the world.
Health Technology Insights: Sunwave Health Earns ONC Health IT Certification for Behavioral Health Providers
Lung cancer remains a leading cause of cancer-related death in Brazil, responsible for approximately 29,000 deaths annually, according to data from the Brazilian National Cancer Institute (INCA). Late diagnosis continues to be a challenge, with the majority of patients diagnosed at an advanced stage, where curative treatment options are limited.
“Securing regulatory approval in Brazil is a key milestone in our expansion across Latin America,” said Benny Krauz, Vice President of Regulatory and Quality at Body Vision Medical. “We’re proud to partner with Supri to make LungVision available to Brazilian physicians and patients, and to help raise the standard of care for early lung cancer diagnosis.”
Health Technology Insights: Abra Dental Expands Access to Quality Care with New Paterson, NJ Office
LungVision transforms any standard C-arm into an AI-powered 3D imaging system, giving physicians real-time navigation and enhanced visualization to perform more precise bronchoscopic biopsies. The technology supports earlier and more accurate diagnoses of pulmonary nodules—helping improve patient outcomes while keeping procedural costs low.
“We are excited to bring LungVision to Brazil,” said Marcos Ramin, CEO of Supri. “This innovative imaging platform aligns perfectly with our mission to offer meaningful medical technologies that improve lives. LungVision’s ability to support early detection and enhance biopsy accuracy represents a major advance for interventional pulmonology in Brazil.”
Health Technology Insights: Revival Healthcare and Olympus Invest $458 Million in Swan EndoSurgical
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
